Isis Pharmaceuticals, Inc.
(ISIS:NASDAQ)
Snapshot of Isis Pharmaceuticals, Inc. (ISIS)
|
OPEN
$11.40
|
PREVIOUS CLOSE
$11.23
|
|
|
DAY HIGH
$11.47
|
DAY LOW
$11.25
|
|
|
52 WEEK HIGH
08/4/09 - $18.81
|
52 WEEK LOW
12/2/08 - $9.90
|
|
|
MARKET CAP
1.1B
|
AVERAGE VOLUME 3 mo
2.7M
|
|
|
DILUTED EPS TTM
$-0.14
|
SHARES OUTSTANDING
98.4M
|
|
|
ISIS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related business week news
Jittery investors dumped shares Tuesday, driving the S&P 500 down over 5% in the first five days of the trading year
Equities were regaining some strength although the weaker housing data indicates more pain ahead
related news
ISIS Details
Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide. The company was founded in 1989 and is based in Carlsbad, California.
ISIS Top Compensated Officers
Key developments for Isis Pharmaceuticals, Inc. (ISIS)
To present mipomersen Phase 3 data in HoFH
Isis Pharmaceuticals Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported total revenue of $26,771,000, loss from operations of $10,396,000, loss from continuing operations, before income tax benefit of $12,028,000, net loss from continuing operations, net of income tax benefit of $8,060,000 or $0.07 per basic and diluted share, net loss attributable to common stockholders of $6,924,000 or $0.07 per basic and diluted share against total revenue of $29,463,000, income from operations of $176,000, income from continuing operations, before income tax benefit of $560,000, net income from continuing operations, net of income tax benefit of $560,000 or $0.02 per basic and diluted share, net income attributable to common stockholders of $1,613,000 or $0.02 per basic and diluted share a year ago. Pro forma loss from operations of $6,850,000 as compared to a income from operations of $3,788,000. Pro forma net loss of $3,378,000 as compared to net income of $5,663,000 a year ago. For the nine months, the company reported total revenue of $89,338,000, loss from operations of $15,867,000, loss from continuing operations, before income tax benefit of $17,252,000, net loss from continuing operations, net of income tax benefit of $12,627,000 or $0.10 per basic and diluted share, net income attributable to common stockholders of $162,024,000 or $1.65 per basic and diluted share against total revenue of $77,540,000, loss from operations of $4,984,000, loss from continuing operations, before income tax benefit of $5,082,000, net loss from continuing operations, net of income tax benefit of $5,082,000 or $0.02 per basic and diluted share, net loss attributable to common stockholders of $7,910,000 or $0.08 per basic and diluted share a year ago. Pro forma loss from operations of $6,053,000 as compared to a income from operations of $5,450,000. Pro forma net income of $170,280,000 as compared to net income of $3,905,000 a year ago.
To present company overview
Stock Quotes
| Recently Viewed | |||
| ISIS | $11.25 USD | +0.02 |  |
|---|---|---|---|
| N | $14.77 USD | +0.46 |  |
| JBL | $13.96 USD | +0.33 |  |
| AF | $10.63 USD | +0.22 |  |
| TRW | $23.22 USD | +0.37 |  |
Market data is delayed at least 20 minutes.
ISIS Competitors
| Company | Last | Change |
| Alnylam Pharmaceuticals Inc | $17.26 USD | +0.42 |
| Celera Group | $6.43 USD | +0.18 |
| Idera Pharmaceuticals Inc | $5.15 USD | +0.32 |
| Sangamo BioSciences Inc | $5.57 USD | +0.055 |
| Tekmira Pharmaceuticals Corp | C$1.01 CAD | +0.01 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ISIS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 9.3x |
|
| Price/Book | 3.8x |
|
| Price/Cash Flow | 7.0x |
|
| TEV/Sales | 2.9x |
|
|
ISIS |
||
ISIS transactions
| Type Date |
Target |
|
Private Placement
November 11, 2009 |
Altair Therapeutics, Inc. |
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- San Diego, CA-ISIS Pharmaceuticals
- San Diego, CA-ISIS Pharmaceuticals
- Carlsbad, CA-ISIS Pharmaceuticals
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Isis Pharmaceuticals, Inc. (ISIS) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
